681004-50-2

Basic information

• Product Name: 3-Methyl-4-(4-methyl-1-piperazinyl)aniline
• Synonyms: 3-Methyl-4-(4-methyl-1-piperazinyl)aniline;3-methyl-4-(4-methyl-1-piperazinyl)benzenamine;3-METHYL-4-(4-METHYLPIPERAZIN-1-YL)ANILINE(WXC06659)
• CAS NO: 681004-50-2
• Molecular Formula: C₁₂H₁₉N₃
• Molecular Weight: 205.29936
• Mol File: 681004-50-2.mol

Chemical Properties

• Boiling Point: 361.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.073±0.06 g/cm3(Predicted)
• PKA: 7.90±0.40(Predicted)
• CAS DataBase Reference: 3-Methyl-4-(4-methyl-1-piperazinyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-4-(4-methyl-1-piperazinyl)aniline(681004-50-2)
• EPA Substance Registry System: 3-Methyl-4-(4-methyl-1-piperazinyl)aniline(681004-50-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 681004-50-2(Hazardous Substances Data)

Upstream product

• 455-88-9 5-nitro-2-fluorotoluene 
• 109-01-3 1-methyl-piperazine 
• 681004-49-9 3-methyl-4-(4-methylpiperazin-1-yl)nitrobenzene 

Downstream Products

• 955369-53-6 C₃₅H₄₅N₉O₅ 
• 1042433-27-1 2-[[5-cyano-2-[3-methyl-4-(4-methylpiperazin-1-yl)aniline]pyrimidin-4-yl]amino]benzamide 
• 1020204-50-5 3-chloro-N-(3-methyl-4-(4-methylpiperazin-1-yl)phenyl)-8-((1-methylpiperidin-4-yl)methoxy)-9H-pyrido[2,3-b]indol-5-amine 
• 1352216-15-9 1-(4-bromo-2-methylphenyl)-4-methylpiperazine 

Relevant articles and documents

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)

Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c-KIT/PDGFRα dual inhibitor, compound 31, with single-digit nanomolar potency against c-KIT and PDGFRα. Compared to Imatinib (1), 31 showed better antiproliferative efficacy against various TEL-c-KIT/PDGFRα-BaF3 isogenic cells, including three 1-resistant BaF3 cell lines, as well as against GIST-T1 and GIST-882 cell lines. Furthermore, compound 31 showed a good KinomeScan selectivity (468 kinases) (S score (1) = 0.01 at 1 μM concentration), good metabolic stability in liver microsomes, and no hERG inhibitory activity. It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors

A series of 2,4 diamino-pyrimidines have been identified from an analysis of open access high throughput anti-malarial screening data reported by GlaxoSmithKline at the 3D7 and resistant Dd2 strains. SAR expansion has been performed using structural knowledge of the most plausible parasite target. Seventeen new analogs have been synthesized and tested against the resistant K1 strain of Plasmodium falciparum (Pf). The cytotoxicity of the compounds was assessed in Vero and A549?cells and their selectivity towards human kinases including JAK2 and EGFR were undertaken. We identified compound 5n and 5m as sub-micromolar inhibitors, with equivalent anti-malarial activity to Chloroquine (CQ). Compounds 5d and 5k, μM inhibitors of Pf, displayed improved cytotoxicity with weak inhibition of the human kinases.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

N-(3,4-disubstituted phenyl) salicylamide derivatives

A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C